tcsc0018185 BMY-25271

BMY-25271 is a histamine H2 receptor antagonist.

IC50 & Target: Histamine H2 receptor^[1]

In Vivo: BMY-25271 is a histamine H2 receptor antagonist. The dose response curves are parallel and oral ED₅₀ values derived from probit analysis are 0.093, 0.97 and 6.9 mg/kg for BMY-25271, ranitidine and cimetidine, respectively. BMY-25271, therefore, is about 10 and 74 times more potent than ranitidine and cimetidine, respectively. Pretreatment with the highest dose of BMY-25271 does not significantly affect the absorption of aspirin or the formation of its major metabolite, salicylic acid^[1].